Kuehn Law Investigates TG Therapeutics Officers and Directors
Shareholder litigation firm Kuehn Law, PLLC is investigating TG Therapeutics, Inc. (NASDAQ: TGTX) officers and directors for potential breaches of fiduciary duty. The probe concerns allegations of self-dealing.
Kuehn Law, PLLC, a law firm specializing in shareholder litigation, has announced an investigation into the conduct of officers and directors at TG Therapeutics, Inc. (NASDAQ: TGTX). The firm is examining allegations that certain individuals may have breached their fiduciary duties owed to the company's shareholders.
The core of the investigation centers on potential instances of self-dealing by corporate insiders. Kuehn Law indicated that shareholders who have held TGTX stock long-term and believe they have been negatively impacted may be entitled to damages and may help seek corporate governance reforms.
Interested shareholders are encouraged to contact Kuehn Law for a free consultation. The firm stated that it covers all case costs and does not charge clients for these services. The firm advised that acting promptly is important, as statutes of limitations may restrict the time available to pursue legal action.
Kuehn Law highlighted the importance of shareholder involvement in maintaining the integrity of financial markets. Further information about shareholder derivative litigation services can be found on the firm's website. The firm's contact details include an email address and phone number.